3.8 Article

The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment

期刊

VALUE IN HEALTH REGIONAL ISSUES
卷 40, 期 -, 页码 13-18

出版社

ELSEVIER
DOI: 10.1016/j.vhri.2023.10.001

关键词

direct costs; elasticity factor; friction period; indirect costs; loss of productivity.

向作者/读者索取更多资源

This study aimed to compare the direct (biological drugs only) and indirect (productivity loss) costs in patients with rheumatoid arthritis during the study period. The results showed that the indirect costs were 2.5 to 3 times lower than the costs of biological and targeted treatment.
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据